Grants and Contracts Details
Description
The goal of the current subcontract is to determine the efficacy of CTBSEKDEL
in a chronic model of colitis. Studies performed at the University of Kentucky will test a dose
range of CTBSEKDEL given to IL-10 KO mice after they were induced with a two week course of
piroxicam as published (DAYS 0 – 14)(1, 2). Treatment will be administered (range of three
doses) after the induction of colitis (DAY 14-28) to mimic human therapy. Treatment effect will
be measured at DAY 28 using clinical parameters as described in the research plan (weight
loss, diarrhea severity, colonic bleeding, etc), and tissue markers of inflammation (mRNA and
protein for chemokine and cytokine as published (4)) and via histology as below (3).
Status | Active |
---|---|
Effective start/end date | 6/20/20 → 3/31/24 |
Funding
- University of Louisville: $221,568.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.